Orthofix Medical announced first commercial U.S. implants of the M6-C™ cervical disc following FDA Premarket Approval of the device, which occurred in 1Q19.
M6-C is designed to restore physiologic motion to the spine at the treated level, and features an artificial viscoelastic nucleus and fiber annulus that mimics the anatomic structure of a natural disc. It presents an alternative to cervical fusion for eligible patients.
The device is in controlled, limited U.S. market launch. Outside of the U.S., M6-C has been implanted more than 45,000 times.
Orthofix Medical announced first commercial U.S. implants of the M6-C™ cervical disc following FDA Premarket Approval of the device, which occurred in 1Q19.
M6-C is designed to restore physiologic motion to the spine at the treated level, and features an artificial viscoelastic nucleus and fiber annulus that mimics the anatomic structure of a...
Orthofix Medical announced first commercial U.S. implants of the M6-C™ cervical disc following FDA Premarket Approval of the device, which occurred in 1Q19.
M6-C is designed to restore physiologic motion to the spine at the treated level, and features an artificial viscoelastic nucleus and fiber annulus that mimics the anatomic structure of a natural disc. It presents an alternative to cervical fusion for eligible patients.
The device is in controlled, limited U.S. market launch. Outside of the U.S., M6-C has been implanted more than 45,000 times.
Copy to clipboard 
